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OBJECTIVE—Smooth muscle cell (SMC) maintained in me-
dium containing normal levels of glucose do not proliferate in
response to IGF-I, whereas cells maintained in medium contain-
ing 25 mmol/l glucose can respond. The aim of this study was to
determine whether signaling events that have been shown to be
required for stimulation of SMC growth were regulated by
glucose concentrations in vivo.
RESEARCH DESIGN AND METHODS—We compared IGF-I–
stimulated signaling events and growth in the aortic smooth
muscle cells from normal and hyperglycemic mice.
RESULTS—We determined that, in mice, hyperglycemia was
associated with an increase in formation of the integrin-associ-
ated protein (IAP)/Src homology 2 domaine containing tyrosine
phosphatase substrate 1 (SHPS-1) complex. There was a corre-
sponding increase in Shc recruitment to SHPS-1 and Shc phos-
phorylation in response to IGF-I. There was also an increase in
mitogen-activated protein kinase activation and SMC prolifera-
tion. The increase in IAP association with SHPS-1 in hyperglyce-
mia appeared to be due to the protection of IAP from cleavage
that occurred during exposure to normal glucose. In addition, we
demonstrated that the protease responsible for IAP cleavage was
matrix metalloprotease-2. An anti-IAP antibody that disrupted
the IAP–SHPS-1 association resulted in complete inhibition of
IGF-I–stimulated proliferation.
CONCLUSIONS—Taken together, our results support a model
in which hyperglycemia is associated with a reduction in IAP
cleavage, thus allowing the formation of the IAP–SHPS-1 signal-
ing complex that is required for IGF-I–stimulated proliferation of
SMC. Diabetes 57:2637–2643, 2008
D
iabetes is an independent risk factor for athero-
sclerotic heart disease (1). Studies have shown
a correlation between glucose levels and risk of
developing atherosclerosis (2–4). Atherosclero-
sis is characterized by an increase in smooth muscle cell
(SMC) migration and proliferation from the vessel wall
into the lumen (5). Both in vitro and in vivo studies have
demonstrated that IGF-I is a stimulator of SMC migration
and proliferation (6–8). When SMCs grown in 5 mmol/l
glucose are exposed to IGF-I, there is no increase in
migration or proliferation (9). However, when glucose is
increased to 25 mmol/l, IGF-I stimulates signiﬁcant in-
creases in migration and proliferation (10). Phosphoryla-
tion of Shc and subsequent activation of the mitogen-
activated protein kinase (MAPK) pathway is absolutely
required for the migration and proliferation of SMCs in
response to IGF-I (11). When SMCs are grown in 25 mmol/l
glucose and then exposed to IGF-I, Shc and MAPK phos-
phorylation are signiﬁcantly increased. In contrast, when
SMCs are grown in 5 mmol/l glucose, there is no increase
in Shc or MAPK phosphorylation (10).
We have determined that in contrast to SMCs grown in
5 mmol/l glucose, when SMCs are exposed to 25 mmol/l
glucose, Src homology 2 domain containing tyrosine phos-
phatase substrate 1 (SHPS-1) binds to the extracellular
domain of IAP, via its extracellular domain. This interac-
tion is required for IGF-I to stimulate SHPS-1 phosphory-
lation, which is required for recruitment and
phosphorylation of Shc (12). The aims of this study were
to determine whether IAP/SHPS-1 interacted in vivo,
whether this interaction was regulated by changes in
blood glucose levels, and whether this interaction regu-
lated cellular responsiveness to IGF-I stimulation.
RESEARCH DESIGN AND METHODS
Human (endotoxin-free) IGF-I was a gift from Genentech (South San Fran-
cisco, CA). Polyvinyl diﬂuoride membranes (Immobilon P) were from Milli-
pore Corporation (Billerica, MA). Autoradiographic ﬁlm was from Pierce
(Rockford, IL). Fetal bovine serum, Dulbecco’s modiﬁed medium, penicillin,
and streptomycin were purchased from Life Technologies (Grand Island, NY).
The monoclonal anti-phosphotyrosine (PY99) and the polyclonal anti–IGF-I
receptor (IGF-IR) antibodies were from Santa Cruz (Santa Cruz, CA). The
phospho/total extracellular signal–related kinase (ERK)1/2 and anti-Shc anti-
bodies were purchased from BD Transduction Laboratories (Lexington, KY).
The anti–SHPS-1 antibody was purchased from Upstate Cell Signaling Solu-
tions (Charlottesville, VA). The -actin was purchased from Chemicon (Te-
mecula, CA). The matrix metalloprotease-2 (MMP-2) inhibitor IV (category
number 444274) was purchased from EMD Biosciences (San Diego, CA). All
other reagents were from Sigma (St. Louis, MO) unless stated.
Anti-IAP antibodies. The anti-IAP monoclonal antibody, B6H12, was puri-
ﬁed from a cell line derived from a B-cell hybridoma (13). The anti-IAP
antibody (referred to as R569), which recognizes amino acids 41 and 61 in the
extracellular domain of IAP, has been described previously (14).
Induction of hyperglycemia in mice. Hyperglycemia was induced in C57/B6
mice (Taconic Hudson NY) using the low-dose streptozotocin (STZ) protocol
(15). After a 4-h fast, mice were injected intraperitoneally with either STZ (50
mg/kg) in citrate buffer (pH 4.5) or citrate buffer alone daily for 5 days. The
protocols used were derived from those published by the Animal Models of
Diabetic Complications Consortium, which were developed to allow direct
comparison of the studies from a large consortium of multiple investigators
(15).
Blood glucose measurements. Blood glucose levels were measured using a
Freestyle Glucose monitor (Abbott Laboratories, Alameda CA). Blood was
obtained from the cheek pouch using GoldenRod animal lancets (Medipoint
International, Mineola, NY). Glucose levels were measured before the admin-
istration of IGF-I and after 15 min, 30 min, and 30 h.
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DIABETES, VOL. 57, OCTOBER 2008 2637Measurement of total cholesterol. Total cholesterol levels were measured
in whole blood using a Cardiocheck meter with cholesterol testing strips
(Polymer Technology Systems, Indianapolis, IN).
Measurement of IGF-I levels. An enzyme-linked immunoassay was used to
measure IGF-I levels in the serum from mice obtained at necropsy by direct
heart puncture (Diagnostic Systems Laboratories, Webster, TX). Samples
were treated as described by the manufacturer. Absorbance was measured by
a plate reader (measuring wavelength: 450 nm, background wavelength: 530
nm) Appropriate standards ranging in concentration from 0 to 4,000 ng/ml and
internal controls (provided by the manufacturer) were used.
Treatment with IGF-I and assessment of SMC proliferation. Fasted
hyperglycemic and control mice were injected intraperitoneally with IGF-I (1
mg/kg), PBS alone, B6H12 (1 mg/kg), control IgG, or B6H12 plus IGF-I 30 h
before death. Aortas were removed and ﬁxed before embedding in parafﬁn.
Serial sections (5 m thick) were cut from the same region of aorta, and every
10th section (four sections/aorta) was incubated with an anti-Ki67 antibody
(Abcam, Cambridge, MA) followed by a biotin-conjugated goat anti-rabbit
secondary antibody. Staining was visualized using the ABC Elite kit (Vector
Laboratories, Burlingame, MA). The number of SMCs staining positive for Ki67
was determined as a percentage of the total number of SMCs in each section.
There were a total of six mice in each treatment group. The data shown are the
mean percentages of Ki67
 cells from all four sections from each of the mice.
Treatment of mice with IGF-I for assessment of signaling events.
Fasted, hyperglycemic, and control mice were injected intraperitoneally with
IGF-I (1 mg/kg) or PBS for 15 and 30 min before death Additional mice were
injected with B6H12 (1 mg/kg) or IgG 30 h before death. Aortas were removed
and immediately snap-frozen.
Homogenization of aorta samples for protein analysis. The aortas were
homogenized in ice-cold buffer, 20 mmol/l Tris, 150 mmol/l sodium chloride
(pH 7.4), 2 mmol/l EDTA, and 0.05% Triton X100, using a glass tissue grinder.
Protein levels were measured (bicinchoninic acid; Pierce), and equal amounts
were either examined directly by Western immunoblotting after SDS-PAGE or
after immunoprecipitation.
Proteins were separated by SDS-PAGE (under nonreducing conditions to
visualize IAP; otherwise, reducing conditions were used) and then visualized
by Western immunoblotting with appropriate antibodies (at concentrations
between 1:500 and 1:1,000).
Analysis of MMP-2 gelatinase activity by zymography. MMP-2 gelatinase
activity was assessed in aorta homogenates and serum-free conditioned
medium from murine aortic SMCs (mSMCs) by gelatin zymography (14).
Isolation of mSMCs. mSMCs were isolated from the aorta of wild-type
C57/B6 male mice and maintained in medium containing either 5 or 25 mmol/l
glucose (16). Medium containing 5 mmol/l glucose was supplemented to 25
mmol/l with mannitol (the addition of mannitol does not affect IAP cleavage
when SMCs are grown in 5 mmol/l glucose [14]). Both types of medium
contained 1.0 mmol/l pyruvate.
Analysis of IAP from lysates of mSMCs. mSMCs were plated in medium
containing either 25 or 5 mmol/l glucose. The medium was changed after 3
days. After an additional 3 days, the monolayers were rinsed three times with
SFM (5 mmol/l glucose supplemented to 25 mmol/l with mannitol) and
incubated 16–17 h. The MMP-2 inhibitor (3 g/ml) or an equivalent amount of
vehicle (dimethylsulphoxide) was added for 4 h. Cells were lysed in modiﬁed
radioimmunoassay buffer. After centrifugation, equal amounts of cellular
protein were mixed with nonreducing gel-loading buffer, heated to 70°C for 10
min and separated by SDS-PAGE (8%). Proteins were visualized by immuno-
blotting (13).
Data quantiﬁcation and statistical analysis. For the biochemical analysis
of aortic extracts, a representative Western immunoblot for each experiment
is shown. Chemiluminescent images obtained from analysis of at least six
mice from each treatment group (from at least three independent sets of mice
analyzed over a period of 12 months) were scanned using a DuoScan T1200
(AGFA, Brussels, Belgium), and band intensities were analyzed using NIH
Image, version 1.61. An unpaired t test and ANOVA were used to compare the
differences in band intensities between the different groups.
RESULTS
Characterization of hyperglycemic mice compared
with control mice. The mean fasting glucose concentra-
tion of mice treated with STZ was 285  47 mg/dl
compared with 118  17 mg/dl in control mice (mean 
SD, n  25). Treatment with IGF-I for 30 h had no
signiﬁcant effect on the glucose levels in either the STZ or
control mice. After 15 min, there was a transient 66  7%
decrease that returned to pretreatment levels by 20 min.
There was no signiﬁcant difference in the body weight
between the mice treated with STZ (31  2 g) and controls
(29  2 g). Cholesterol levels in the control and STZ-
treated mice showed no signiﬁcant difference (e.g., STZ-
treated, 104  3 mg/dl; control, 104  6 mg/dl; NS). There
was no signiﬁcant difference in the levels of IGF-I (STZ-
treated, 130  7 ng/ml; control, 130  5 ng/ml; NS).
Administration of IGF-I resulted in a 5  0.1-fold increase
in serum IGF-I at 15 min; however, after 30 h, it had
returned to baseline.
Shc phosphorylation, Shc recruitment to SHPS-1, and
SHPS-1 phosphorylation are increased in aorta from
hyperglycemic mice. The proliferative response of cul-
tured SMCs to IGF-I is determined by the extent of Shc
phosphorylation (11). The aortic homogenates from the
hyperglycemic mice showed a signiﬁcant 2.8-fold increase
in phosphorylated p52 Shc compared with the control
mice (scanning units 34,570  16,048 [hyperglycemic],
12,160  2,459 [control], mean  SD [n  12, P  0.005])
(Fig. 1A).
There was a fourfold increase in the amount of Shc
associated with SHPS-1 in the hyperglycemic mice com-
pared with the control mice (Fig. 1B, top panel). The
scanning units for the hyperglycemic mice were 29,779 
14,414 compared with control (7,619  5,848 [mean  SD,
n  12, P  0.005]).
Shc recruitment to SHPS-1 requires SHPS-1 phosphory-
lation (11). When SHPS-1 phosphorylation in aorta homog-
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FIG. 1. A: Shc phosphorylation and Shc recruitment to SHPS-1 and
SHPS-1 phosphorylation in aorta homogenates from hyperglycemic
compared with control mice. A: Aortas from hyperglycemic (STZ) and
control (CON) mice were homogenized. Shc phosphorylation was
determined following immunoprecipitation (IP) with an anti-Shc anti-
body and immunoblotting (IB) with an anti-phosphotyrosine antibody
(p-Tyr). Total Shc levels were determined by immunoblotting with an
anti-Shc antibody after Shc immunoprecipitation. The graph shows the
difference in Shc phosphorylation when the aortas from the STZ mice
are compared with the CON mice expressed as arbitrary scanning units
(mean  SD, n  12, ***P < 0.005). B: Aortas from hyperglycemic
(STZ) and control (CON) mice were homogenized. Shc recruitment to
SHPS-1 was determined after immunoprecipitation with an anti–
SHPS-1 antibody and immunoblotting with an anti-Shc antibody (Shc)
(top panel). SHPS-1 phosphorylation was determined from using the
same homogenate by immunoprecipitation with the anti–SHPS-1 anti-
body and immunoblotting with an antiphosphotyrosine (p-Tyr) anti-
body (middle panel). Total SHPS-1 levels were determined after
immunoprecipitation and immunoblotting with the anti–SHPS-1 anti-
body. The graph shows the difference in Shc recruitment to SHPS-1
between the aortas from the STZ compared with the CON mice
expressed as arbitrary scanning units (mean  SD, n  12, ***P <
0.005).
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compared, there was a sevenfold increase in SHPS-1
phosphorylation (Fig. 1B, middle panel). The scanning
units for the hyperglycemic mice were 27,466  14,652
compared with control (4,146  3,305 [mean  SD, n  8,
P  0.005]).
Hyperglycemia regulates IAP cleavage. In order for
SHPS-1 to be phosphorylated, it must be associated with
IAP (12). Our recent in vitro studies have determined that
in SMCs cultured in 5 mmol/l glucose, SHPS-1 phosphor-
ylation and formation of the SHPS-1–SHP-2–c-Src–Shc
signaling complex (which is required for cellular replica-
tion) is impaired because of constitutive cleavage of IAP,
which disrupts SHPS-1 binding (14). When the status of
IAP in the aortic homogenates was determined, there was
a signiﬁcant (ﬁvefold) increase in intact IAP detected in
the homogenates from the hyperglycemic mice compared
with controls. The samples were immunoblotted using an
anti-IAP antibody (R569) that is speciﬁc for intact IAP
(Fig. 2A, upper panel). The homogenates were also immu-
noblotted with an anti-IAP antibody that can detect both
intact and fragmented IAP (Fig. 2A, lower panel). In the
aortas obtained from the hyperglycemic mice, 82  13.9%
(mean  SD, n  10) of the total IAP was intact. This was
signiﬁcantly greater than the 20  11.52% (mean  SD, n 
10, P  0.005) of the total IAP that was intact in aortas
from the control mice. Our previous studies determined
that in SMCs cultured in normal glucose, IAP cleavage is
mediated by an increase in MMP-2 protease activity (14).
Analysis of the aorta homogenates from the STZ mice
using gelatin zymography showed that there was a 68.5 
0.05% decrease in the amount of protease activity associ-
ated with the pro-form of MMP-2 and a similar 59.3  3%
decrease in the amount of protease activity associated
with the active form of MMP-2 compared with the control
mice (Fig. 2, bottom panel; mean  SD, n  3, P  0.05).
Hyperglycemia is associated with an increase in throm-
bospondin-1 and enhanced IAP–thrombospondin-1
binding. The IAP ligand thrombospondin (TS)-1 enhances
the response of SMC to IGF-I, in part through its binding to
IAP (13). There is signiﬁcantly more TS-1 associated with
IAP in SMCs maintained in 25 mmol/l glucose compared
with 5 mmol/l glucose (9). Therefore, we determined if the
increase in intact IAP in hyperglycemic mice was associ-
ated with an increase in TS-1 binding to IAP. There was a
sixfold increase in the amount of TS-1 in the aortas of the
hyperglycemic mice. The scanning units were 21,968 
12,948 (hyperglycemic) and 3,715  3,059 (control)
(mean  SD, n  8, P  0.005). Furthermore, there was a
signiﬁcant 3.8  1.3-fold (mean  SD, n  8, P  0.005)
increase in the amount of TS-1 that could be coprecipi-
tated with IAP (Fig. 2B).
IAP–SHPS-1 association regulates IGF-I–stimulated
signaling events in hyperglycemic mice. Consistent
with the increase in intact IAP in the hyperglycemic mice,
we detected a fourfold increase in the amount of IAP that
could be coprecipitated with SHPS-1 in the aorta homog-
enates from hyperglycemic mice compared with controls
(Fig. 3A). The scanning units were 27,463  6,453 (hyper-
glycemic) and 960  7,046 (control) (mean  SD, n  6,
P  0.05).
The anti-IAP antibody B6H12 disrupts the association
between the two proteins and consequently it inhibits
IGF-I signaling (12). To determine whether IAP–SHPS-1
association was required for IGF-I signaling in vivo, we
treated the hyperglycemic mice with IGF-I with or without
the systemic administration of B6H12. Treatment with
B6H12 induced an eightfold decrease between IAP and
SHPS-1 association (Fig. 3A) (scanning units 5,517  550
[B6H12] and 27,463  6,453 [hyperglycemic control]
[mean  SD, n  6, P  0.05]). Basal SHPS-1 phosphory-
lation was higher in the hyperglycemic mice compared
with controls. After IGF-I, there was a 10-fold increase in
SHPS-1 phosphorylation (Fig. 3B, top panel). Administra-
tion of B6H12 signiﬁcantly decreased SHPS-1 phosphory-
lation in both the hyperglycemic (a twofold decrease) and
the hyperglycemic mice treated with IGF-I (a fourfold
decrease) (Fig. 3B, top panel). The scanning units were as
follows: control mice: 1,725  980, hyperglycemic mice:
13,751  7,117, the hyperglycemic mice treated with IGF-I:
17,162  6,704, hyperglycemic mice treated with B6H12:
7,041  2,931, and hyperglycemic mice treated with IGF-I
and B6H12: 6,539  4,653 (mean  SD, n  6, P  0.05).
Our previous studies have shown that activation of
MAPK and stimulation of SMC proliferation in response to
IGF-I requires formation of an IAP–SHPS-1–Shc signaling
complex and Shc phosphorylation. Immunoblotting
showed an eightfold increase in ERK1/2 phosphorylation
in hyperglycemic mice compared with control mice (Fig.
3B, middle panel). Treatment of the hyperglycemic mice
with IGF-I resulted in a 9.8-fold increase in ERK1/2 phos-
phorylation (compared with no IGF-I treatment). Treat-
ment with B6H12 signiﬁcantly inhibited the increase in
ERK1/2 phosphorylation both in the presence or absence
of IGF-I in the hyperglycemic mice (Fig. 3B, middle
panel).
Increased cell proliferation in response to IGF-I in
hyperglycemic mice. To demonstrate if these differences
in signaling observed in the aortas from hyperglycemic
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FIG. 2. Hyperglycemia regulates cleavage of IAP and TS-1 association
with IAP. A: Homogenates from hyperglycemic (STZ) and control
(CON) mice were separated by SDS-PAGE and IAP protein levels
visualized by Western immunoblotting (IB) with the anti-IAP antibody
that selectively recognizes intact IAP (R569) and the anti-IAP mono-
clonal antibody B6H12 that detects intact and fragmented IAP. MMP-2
activity in homogenates from both groups of mice was assessed by
gelatin zymography. The graph shows the difference in the amount of
intact IAP between the aortas from the STZ compared with the CON
mice expressed as percent (mean  SD, n  10, ***P < 0.005). B:
Homogenates from hyperglycemic (STZ) and control (CON) mice were
either immunoblotted (IB) with an anti–TS-1 antibody (top panel),
immunoprecipitated (IP) with the anti-IAP antibody B6H12 before
immunoblotting with the anti–TS-1 antibody (middle panel), or immu-
noblotted with the anti–-actin antibody. The graph shows the differ-
ence in the amount of TS-1 between the aortas from the STZ compared
with the CON mice expressed as arbitrary scanning units (mean  SD,
n  8, ***P < 0.005).
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cemic and control mice were injected with IGF-I, and
percentage of SMCs that were Ki67
 was quantiﬁed.
Treatment of the control mice with IGF-I increased the
percentage of SMCs positive for Ki67 from 3.6  1.2% (PBS
alone) to 9  4.5% (mean  SD, n  6). Hyperglycemia
alone increased the number to 5.9  1% (mean  SD, n 
6; P  0.05). Treatment of hyperglycemic mice with IGF-I
resulted in a signiﬁcant increase in the percentage of
Ki67
 cells to 19  2.5% (mean  SD, n  6; P  0.05 when
compared with both control and hyperglycemic mice)
(Fig. 4). Analysis of IGF-I receptor protein levels showed
no difference between the control mice and STZ-treated
mice. (STZ, 103  3% of the levels in the control mice
[mean  SD, n  12]). To determine whether the hyper-
glycemia-induced increase in IAP association with SHPS-1
was related to enhanced SMC proliferation, hyperglycemic
mice were injected with the anti-IAP antibody (B6H12) to
disrupt IAP and SHPS-1 association (Fig. 3). After B6H12,
the increase in Ki67
 cells induced by either hyperglyce-
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FIG. 3. Disrupting the association between IAP and SHPS-1 inhibits SHPS-1 phosphorylation and downstream signaling in response to IGF-I. A:
Homogenates from control (CON), hyperglycemic (STZ), and hyperglycemic mice that had been treated with the anti-IAP antibody (B6H12) in
vivo were immunoprecipitated (IP) with the anti–SHPS-1 antibody, and IAP association with SHPS-1 was determined by immunoblotting for IAP
(B6H12) (top panel). Equal quantities of homogenate from each sample were also immunoblotted with an anti–-actin antibody (bottom panel).
The graph shows the difference in IAP association with SHPS-1 between the aortas from the STZ (with or without injection with B6H12) compared
with the CON mice, expressed as arbitrary scanning units (mean  SD, n  6, *P < 0.05). B: Homogenates from control, hyperglycemic (STZ),
and hyperglycemic mice treated with the anti-IAP antibody B6H12 and/or IGF-I were immunoprecipitated with the anti–SHPS-1 antibody and
immunoblotted with the anti-phosphotyrosine antibody (p-Tyr) (top panel). Homogenates were also immunoblotted directly with the
anti-phospho ERK1/2 antibody. To demonstrate that there was no difference in the amount of protein in each sample, equal quantities of aortic
homogenates were also immunoblotted with the anti–-actin antibody (bottom panel). The graph shows the difference in SHPS-1 phosphorylation
between the aortas from the different treatment groups expressed as arbitrary scanning units (mean  SD, n  6, **P < 0.01 when STZ-treated
mice are compared with control, ##P < 0.01 when IGF-I treatment of STZ mice is compared with STZ-treated mice alone, and P < 0.05 when
treatment with B6H12 is compared with STZ alone).
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FIG. 4. Hyperglycemia enhances the proliferative response of SMCs to
IGF-I in vivo. Control (PBS) and hyperglycemic mice (STZ) were
treated with IGF-I for 30 h (in the presence of the anti-IAP antibody
B6H12 or control IgG). The aortas were removed and parafﬁn sections
prepared. After staining with an anti-Ki67 antibody, the number of
proliferating cells in the layer was counted and expressed as the
percentage of Ki67 cells. The mean data from six mice per treatment
group (with four sections counted/mouse) is shown graphically, and
representative images are also shown. *P < 0.05 when the number of
Ki67 cells are compared with control mice. **P < 0.01 when Ki67
staining in the presence of B6H12 is compared with STZ or STZ plus
IGF-I.
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inhibited (3  0.9 and 3.5  1% of cells, respectively, were
Ki67
; mean  SD, P  0.01).
MMP-2 cleaves IAP in murine SMCs. We determined
previously, using both RNA interference and metallopro-
tease inhibitors, that the protease in porcine SMCs respon-
sible for the cleavage of IAP is MMP-2 (14). Therefore, we
analyzed the ability of the MMP-2 inhibitor (14) to protect
IAP from cleavage in mSMCs grown in 5 mmol/l glucose.
Basally, there was a signiﬁcant (65  5%) decrease in the
amount of intact IAP compared with mSMCs grown in 25
mmol/l glucose. When SMCs were incubated with the
MMP-2 inhibitor, the level of intact IAP in the SMCs grown
in 5 mmol/l glucose increased to 113  7% of the level of
intact IAP in SMCs grown in 25 mmol/l glucose (Fig. 5A).
To conﬁrm that MMP-2 activation is regulated by changes
in glucose, we compared the amount of active MMP-2 in
the conditioned medium from murine SMCs grown in 5
and 25 mmol/l glucose. There was a signiﬁcant (2.6-fold)
increase in active MMP-2, as detected by gelatin zymogra-
phy, in the conditioned medium from mSMCs in 5 mmol/l
glucose compared with the conditioned medium from
mSMCs in 25 mmol/l glucose (Fig. 5B).
DISCUSSION
SMCs grown in medium containing 5 mmol/l glucose do
not proliferate or migrate in response to IGF-I (9). In
contrast, SMCs grown in 25 mmol/l glucose show signiﬁ-
cant increases after IGF-I stimulation (9). This difference
in the responsiveness of SMCs in vitro is due to impaired
IAP association with SHPS-1, preventing the recruitment
and phosphorylation of Shc (9). The results of this study
show that IAP is cleaved constitutively in aortic extracts
from normoglycemic animals and does not bind to SHPS-1.
In contrast, the induction of hyperglycemia in mice is
associated with inhibition of IAP cleavage. This allows
SHPS-1 and Shc phosphorylation and stimulation of DNA
synthesis in response to IGF-I. Although we cannot rule
out the possibility that other changes induced by STZ also
contribute to changes in IAP cleavage, our data strongly
support our conclusion that hyperglycemia is a critical
regulator of IAP cleavage and thus allows IGF-I signaling
leading to increased SMC replication (Fig. 6).
Hyperglycemia has been associated with an increase in
SMC proliferation in response to several growth factors,
including IGF-I in vitro (9,17–19). While studies in exper-
imental animal models show that manipulation of IGF-I
levels in vascular tissue is related to changes in neointimal
formation and SMC proliferation, those studies have not
assessed the effect of hyperglycemia on vascular cell
proliferation (7,8,20,21). Our results clearly demonstrate
that the presence of hyperglycemia results in enhanced
responsiveness of vascular SMC to IGF-I in mice. Impor-
tantly, they also demonstrate that the signaling mechanism
that accounts for enhanced SMC responsiveness to IGF-I
in vitro (14) is activated in this animal model, thus leading
to the conclusion that it accounts for the increase in cell
replication.
Shc phosphorylation was signiﬁcantly increased in the
aorta from hyperglycemic mice, clearly demonstrating that
the effect of glucose concentration on Shc phosphoryla-
tion is not an artifact of culture conditions or an in vitro
phenomenon. For Shc to be phosphorylated in response to
IGF-I, it must be recruited to phosphorylated tyrosine
residues within the cytoplasmic domain of SHPS-1 (11). In
normoglycemic mice, there is minimal SHPS-1 phosphor-
ylation, but in hyperglycemic animals, there is a marked
increase in basal and IGF-I–stimulated SHPS-1 phosphor-
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FIG. 5. Hyperglycemia-regulated activation of MMP-2 regulates IAP cleavage in murine SMCs. A: Murine SMCs were grown in medium containing
either 25 or 5 mmol/l glucose before overnight incubation in serum-free medium. mSMCs grown in both 25 and 5 mmol/l glucose were then exposed
to either an MMP-2 inhibitor (MMP-2i) or vehicle alone before lysis. Intact IAP was visualized after immunoblotting with the anti-IAP antibody
that recognizes intact IAP (R569). Blots were then stripped and reprobed with the anti–SHPS-1 antibody. The graph shows the amount of IAP
expressed as arbitrary scanning units (mean  SD, n  3, **P < 0.01 when IAP levels in lysate from SMCs grown in 5 mmol/l glucose are compared
with lysate from SMCs grown in 25 mmol/l glucose and ##P < 0.01 when IAP levels in SMCs grown in 5 mmol/l glucose are compared with lysates
grown in 5 mmol/l glucose and treated with the MMP-2 inhibitor). The scanning units were as follows: 25 mmol/l glucose 27,321  3,862, 25 mmol/l
glucose plus MMP-2 inhibitor 28,052  3,641, 5 mmol/l glucose 9,697  2,516, 5 mmol/l glucose plus MMP-2 inhibitor 30,637  2,117 (mean  SD,
n  3, P < 0.01). B: Conditioned medium collected from mSMCs grown in 25 and 5 mmol/l glucose and incubated overnight in serum-free medium
was analyzed by gelatin zymography (top panel). The graph shows the difference in MMP-2 gelatinase activity expressed as arbitrary scanning
units (mean  SD, n  3, *P < 0.05). The scanning units for medium collected from mSMCs in 25 mmol/l glucose were 2,173  576 and for mSMCs
in 5 mmol/l glucose they were 5,593  1,671 (mean  SD, n  3, P < 0.05).
L.A. MAILE AND ASSOCIATES
DIABETES, VOL. 57, OCTOBER 2008 2641ylation. The elevated basal levels presumably reﬂect en-
hanced tissue responsiveness to endogenous IGF-I. The
increase in SHPS-1 phosphorylation results in enhanced
Shc recruitment to SHPS-1 and Shc phosphorylation (11).
That this enhanced IGF-I responsiveness in the hypergly-
cemic animals has important consequences was conﬁrmed
in the experiments that showed increased MAPK activa-
tion and SMC proliferation.
IAP cleavage results in loss of SHPS-1 association,
which disrupts the ability of IGF-I to stimulate MAPK
pathway activation and SMC proliferation. Our results
show that, in normoglycemic mice, the extracellular do-
main of IAP is cleaved, resulting in impaired IAP–SHPS-1
association and SHPS-1 phosphorylation. The importance
of this association for IGF-I actions is underscored by the
result of the experiment in which we disrupted IAP/
SHPS-1 using the anti-IAP antibody B6H12. This resulted
in attenuation of SHPS-1 phosphorylation and downstream
signaling basally and in response to IGF-I. More impor-
tantly, this disruption of IAP–SHPS-1 resulted in complete
inhibition of the IGF-I–stimulated increase in cell prolifer-
ation. This strongly supports the conclusion that failure of
IAP–SHPS-1 to associate in normoglycemic conditions
leads to attenuation of IGF-I signaling events.
Sajid et al. (22) demonstrated that after balloon injury in
baboons, there is a signiﬁcant increase in IAP in the
neointima and media, whereas in uninjured vessels, IAP is
only detected in endothelium A signiﬁcant increase in TS-1
was detected in the same areas after injury (22). Consis-
tent with our ﬁndings TS-1 binding to IAP was associated
with enhanced SMC proliferation in vitro. While the mech-
anism that resulted in the increase in detection of intact
IAP in the injured vessel was not determined in that study,
it seems reasonable to propose that increased cellular
levels of IAP and TS-1 are common responses of vascular
SMCs to stress (e.g., mechanical injury or hyperglycemia).
The increase in IAP and its association with TS-1 leads to
enhanced responsiveness of SMCs to IGF-I.
Our ﬁnding of increased TS-1 in aorta from hyperglyce-
mic mice is consistent with prior studies that detected
increased levels of TS-1 in blood vessels of diabetic Zucker
rats (23). Other models of diabetes have also demon-
strated increases in TS-1 in cardiac ﬁbroblasts (24), myo-
cytes (25,26), and SMCs (27). TS-1 binding to IAP
enhances IGF-I signaling by its ability to modulate the
association between IAP and SHPS-1 (13). Because the
increase in TS-1 that was detected in the hyperglycemic
mice was associated with an increase in the amount of
TS-1 associated with the IAP, it seems likely that this
change is related to the increase in IAP/SHPS-1 associa-
tion. Thus, the increased expression of TS-1 in response to
hyperglycemia and the associated enhancement of IGF-I
signaling is likely to be an important contributor to in-
creased cell proliferation.
In a prior study using MMP-2 RNAi, we determined that
the protease responsible for IAP cleavage in porcine SMCs
was MMP-2 (14). Our studies using SMCs isolated from
murine aorta and an MMP-2 inhibitor strongly support our
conclusion that MMP-2 is the protease responsible for IAP
cleavage (14). In this study, we demonstrate that there is
more MMP-2 activity associated with the aorta from hy-
perglycemic mice than from control mice. Taken together,
these ﬁndings suggest that hyperglycemia is functioning to
regulate the amount of active MMP-2 in the extracellular
environment, thereby regulating IAP cleavage (Fig. 6).
Understanding the role of MMPs in atherosclerosis is
complicated by evidence suggesting they play a dual role
by regulating SMC migration, matrix deposition, and insta-
bility caused by matrix destruction (28). The role of MMPs
is further complicated by the use of inhibitors that are not
speciﬁc for just one MMP and by the possibility of com-
pensatory function of another MMP when one is inhibited.
In MMP-2/Apo E
/ mice fed a high-fat diet, lesion size
was reduced compared with control mice, apparently as a
result of decreased SMC migration (29). In another study,
after balloon injury to rats, inhibition of MMP-2 and -9
resulted in decreased SMC migration and early lesion
development, but the intimal lesions eventually increased
to control levels because of an increased SMC replication
rate in the rats treated with the MMP inhibitor (30,31).
These ﬁndings are consistent with our results that suggest
that inhibition of MMP-2 cleavage of IAP enhances SMC
proliferation in response to IGF-I. It is interesting to note
that Webb et al. (31) observed that, unlike the other MMPs,
MMP-2 was produced constitutively in normal rat vessels,
but that there was a decrease in levels immediately after
injury, rebounding again over time. Other studies have
demonstrated either a decrease in MMP-2 (32,33) or an
FIG. 6. Proposed model by which hyperglycemia enhances IGF-I signal-
ing in SMCs in vivo. Hyperglycemia protects IAP from cleavage by
downregulating MMP-2 protease activity that enhances IAP binding to
both TS-1 and SHPS-1. This in turn enhances SHPS-1 phosphorylation
in response to IGF-I, generating a high-afﬁnity binding site to recruit
the SHP-2–c-Src–Shc. Phosphorylation of Shc then leads to activation
of downstream signaling pathways including MAPK, which in turn lead
to SMC proliferation.
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2642 DIABETES, VOL. 57, OCTOBER 2008increase in its inhibitor TIMP-1 (34) in cells or tissues from
diabetic animals. Thus, our studies support the conclusion
that disruption of the association between IAP and SHPS-1
by modulating MMP-2 activity may provide opportunities
for delaying the progression of lesion formation that
occurs in response to hyperglycemia.
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